<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03740568</url>
  </required_header>
  <id_info>
    <org_study_id>FSD-PRG-2018-09</org_study_id>
    <nct_id>NCT03740568</nct_id>
  </id_info>
  <brief_title>Effect of Intervention on Progesterone Levels Before Euploid Embryo Transfer in Pregnancy Outcomes.</brief_title>
  <official_title>Effect of Intervention on Progesterone Levels Before Euploid Embryo Transfer in Pregnancy Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Universitari Dexeus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Santiago Dexeus Font</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dexeus Clinic Woman</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Universitari Dexeus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transferring an euploid embryo avoids one of the main reasons of miscarriage and implantation
      failure (1), overcoming confounding factors such as embryo ploidy or maternal age. Frozen
      Euploid Embryo Transfer (FEET) is routinely performed under standard hormone replacement
      therapy (HRT) and could be considered the best model for evaluating the impact of the
      endometrial preparation in clinical pregnancy rate and also in miscarriage rate.

      Recently several authors have paid attention to serum progesterone (P) as a possible factor
      influencing Frozen Embryo Transfer (FET) outcomes. P plays an important role in endometrial
      gland formation, embryonic implantation and pregnancy maintenance. Labarta et al. (2)
      described in blastocyst FET performed under HRT that serum P &lt;9.2 ng/mL measured on the
      transfer day is associated to significantly lower ongoing pregnancy rate (OR 0.297, 95%
      CI:0.113-0.779).

      Recently the investigators have analyzed 244 FEET performed under HRT in a retrospective
      study (3). Preimplantation genetic testing for aneuploidies (PGT-A) was carried out as
      previously described (4). Embryos that reached the blastocyst stage were biopsied and frozen
      immediately afterwards using the vitrification method (5). Euploid embryos were transferred
      in a subsequent cycle under HRT. Serum P was analyzed the day previous to FEET. Patients with
      serum P &lt;10.6 ng/mL had significantly higher miscarriage rate (26.6% vs 9.5%, p=0.007) and
      lower live birth rate (47.5% vs 62.3 %, p= 0.029) than those with serum P &gt;10.6 ng/mL. The
      investigators also observed that patients with serum P &gt;13.1 ng/mL had the lowest miscarriage
      rate (9.1%) and the highest live birth rate (65.6%). The worst outcomes were observed when
      serum P was &lt;8.06 ng /mL (41% live birth rate and 32.4% miscarriage rate).

      As miscarriage was higher among FEET cycles with serum P &lt;10.6 ng/ml, the investigators
      hypothesize that altering the progesterone supplementation scheme could potentially reduce
      miscarriage rates and increase live birth rate. The purpose of this study is to modify the
      standard progesterone supplementation in FEET under HRT (vaginal micronized progesterone 200
      mg every 8 hours) (6) according to serum P measured not only on the day prior to transfer but
      also on Beta subunit of Human Chorionic Gonadotropin (β-hCG) analysis day, and to probe if
      this intervention reduces miscarriage rate and increases pregnancy outcome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing Pregnancy Rate (OPR)</measure>
    <time_frame>12 weeks after transfer procedure</time_frame>
    <description>Ongoing Pregnancy Rate (OPR) beyond pregnancy week 12 in FEET according to serum P level and interventions on D4 and D5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Miscarriage Rate (MR)</measure>
    <time_frame>12 weeks after transfer procedure</time_frame>
    <description>Miscarriage Rate (MR) in FEET according to serum P level and interventions on D4 and D5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of serum P level</measure>
    <time_frame>D4, D5 and D14 of P supplementation</time_frame>
    <description>P level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of cancellation due to lack of response in case of additional Psc dose on D4.</measure>
    <time_frame>Day 5 of progesterone supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of rescued cycles in case of additional Psc dose</measure>
    <time_frame>Day 5 of progesterone supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing Pregnancy Rate and Live Birth Rate according to serum P level and interventions n D14</measure>
    <time_frame>On day 14 of progesterone supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth Rate (LBR)</measure>
    <time_frame>40 weeks after transfer procedure</time_frame>
    <description>Live birth Rate (LBR) in FEET according to serum P level and interventions on D4 and D5 and D14.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">590</enrollment>
  <condition>Infertility</condition>
  <condition>Progesterone</condition>
  <condition>Frozen Embryo Transfer</condition>
  <condition>Euploid Embryo Transfer</condition>
  <condition>Pregnancy Outcome</condition>
  <condition>Artificial Cycle</condition>
  <condition>Ongoing Pregnancy</condition>
  <arm_group>
    <arm_group_label>Normal Progesterone group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Progesterone level &gt;10.64 ng/mL on day 4 of progesterone supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Progesterone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progesterone level &lt;10.64 ng/mL on day 4 of progesterone supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Progesterone</intervention_name>
    <description>Additional daily dosage of subcutaneous progesterone (Psc) 25 mg/day at night since D4 (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night) New Progesterone analysis on D5 before warming the embryo. Group 2a (Canceled Group, P on D5 &lt;10.64 ng/mL): cancel PGT-FET. Scheduling a new procedure under different P supplementation.
Group 2b (Restored Progesterone Group, P on D5 &gt;10.64 ng/mL): continue HRT as previously described (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night). Warming and transfer the same day (D5)
Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:
If P is &gt;10.64 ng /mL: the same P supplementation is continued. If P is &lt;10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night</description>
    <arm_group_label>Low Progesterone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Progesterone</intervention_name>
    <description>Same Progesterone supplementation (vaginal micronized P 200mg/200mg/200mg) Warming and transfer on D5
Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:
If P is &gt;10.64 ng /mL: the same P supplementation is continued. If P is &lt;10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night</description>
    <arm_group_label>Normal Progesterone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FEET of at least one single embryo

          -  HRT

          -  Endometrial thickness &gt;= 6 mm measured day 4 of progesterone supplementation

        Exclusion Criteria:

          -  Patients with mosaic embryos.

          -  Uterine abnormality.

          -  Natural cycle protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bueaventura Coroleu, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitari Dexeus. Departamento de Ginecología, Obstetricia y Reproducción</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ignacio Rodriguez, Bsc</last_name>
    <phone>0034932274700</phone>
    <phone_ext>22029</phone_ext>
    <email>nacrod@dexeus.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Departamento Ginecología, Obstetricia y Reproducción . Hospital Universitari Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Alvarez, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.dexeus.com/</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Rubio C, Bellver J, Rodrigo L, Castillón G, Guillén A, Vidal C, Giles J, Ferrando M, Cabanillas S, Remohí J, Pellicer A, Simón C. In vitro fertilization with preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized, controlled study. Fertil Steril. 2017 May;107(5):1122-1129. doi: 10.1016/j.fertnstert.2017.03.011. Epub 2017 Apr 19.</citation>
    <PMID>28433371</PMID>
  </reference>
  <reference>
    <citation>Labarta E, Mariani G, Holtmann N, Celada P, Remohi J, Bosch E. Corrigendum: Low serum progesterone on the day of embryo transfer is associated with a diminished ongoing pregnancy rate in oocyte donation cycles after artificial endometrial preparation: a prospective study. Hum Reprod. 2018 Jan 1;33(1):178. doi: 10.1093/humrep/dex353.</citation>
    <PMID>29177428</PMID>
  </reference>
  <reference>
    <citation>Gaggiotti-Marre S, Martinez F, Coll L, Garcia S, Álvarez M, Parriego M, Barri PN, Polyzos N, Coroleu B. Low serum progesterone the day prior to frozen embryo transfer of euploid embryos is associated with significant reduction in live birth rates. Gynecol Endocrinol. 2019 May;35(5):439-442. doi: 10.1080/09513590.2018.1534952. Epub 2018 Dec 26.</citation>
    <PMID>30585507</PMID>
  </reference>
  <reference>
    <citation>Coll L, Parriego M, Boada M, Devesa M, Arroyo G, Rodríguez I, Coroleu B, Vidal F, Veiga A. Transition from blastomere to trophectoderm biopsy: comparing two preimplantation genetic testing for aneuploidies strategies. Zygote. 2018 Jun;26(3):191-198. doi: 10.1017/S0967199418000084. Epub 2018 May 25.</citation>
    <PMID>29798732</PMID>
  </reference>
  <reference>
    <citation>Solé M, Santaló J, Boada M, Clua E, Rodríguez I, Martínez F, Coroleu B, Barri PN, Veiga A. How does vitrification affect oocyte viability in oocyte donation cycles? A prospective study to compare outcomes achieved with fresh versus vitrified sibling oocytes. Hum Reprod. 2013 Aug;28(8):2087-92. doi: 10.1093/humrep/det242. Epub 2013 Jun 5.</citation>
    <PMID>23744895</PMID>
  </reference>
  <reference>
    <citation>Martínez F, Boada M, Coroleu B, Clua E, Parera N, Rodríguez I, Barri PN. A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH. Hum Reprod. 2006 Aug;21(8):2121-5. Epub 2006 Apr 21.</citation>
    <PMID>16632462</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut Universitari Dexeus</investigator_affiliation>
    <investigator_full_name>Buenaventura Coroleu</investigator_full_name>
    <investigator_title>Head Reproductive Service</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

